drugset / Trial / NCT04061772
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma
Timeline
- Start
- 2019-08-12
- Primary completion
- 2021-07-05
- Completion
- 2021-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Pharmorubicin | Unknown | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 100 mg | Oral |